Your browser doesn't support javascript.
loading
A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy.
Sun, Yuanjue; Shu, Yongqian; Liu, Baorui; Liu, Ping; Wu, Changping; Zheng, Rongsheng; Zhang, Xiaohua; Zhuang, Zhixiang; Deng, Yongchuan; Zheng, Leizhen; Xu, Qing; Jiang, Bin; Ouyang, Xuenong; Gao, Jianfei; Xu, Nong; Li, Xiaoyi; Jiang, Su; Liang, Chaofan; Yao, Yang.
Afiliação
  • Sun Y; Oncology Department, The 6th People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 200233, P.R. China.
  • Shu Y; Oncology Department, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China.
  • Liu B; Oncology Department, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu 210008, P.R. China.
  • Liu P; Oncology Department, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China.
  • Wu C; Oncology Department, The First People's Hospital of Changzhou, Changzhou, Jiangsu 213003, P.R. China.
  • Zheng R; Oncology Department, The First Affiliated Hospital of BengBu Medical College, Bengbu, Anhui 233004, P.R. China.
  • Zhang X; Surgical Oncology Department, The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, Zhejiang 325000, P.R. China.
  • Zhuang Z; Oncology Department, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, P.R. China.
  • Deng Y; Surgical Oncology Department, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, P.R. China.
  • Zheng L; Oncology Department, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200092, P.R. China.
  • Xu Q; Oncology Department, Shanghai Tenth People's Hospital, Shanghai 200072, P.R. China.
  • Jiang B; Oncology Department, Third People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 201999, P.R. China.
  • Ouyang X; Oncology Department, Fuzhou General Hospital of Nanjing Military Command of Chinese PLA, Fuzhou, Fujian 350025, P.R. China.
  • Gao J; Cancer Hematology Department, Wuhan General Hospital of Guangzhou Military Command of Chinese PLA, Wuhan, Hubei 510000, P.R. China.
  • Xu N; Oncology Department, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, P.R. China.
  • Li X; Lee's Pharmaceutical (Hong Kong) Ltd., Hong Kong, P.R. China.
  • Jiang S; Zhaoke Pharmaceutical (Heifei) Co. Ltd., Hefei, Anhui 230088, P.R. China.
  • Liang C; Lee's Pharmaceutical (Hong Kong) Ltd., Hong Kong, P.R. China.
  • Yao Y; Oncology Department, The 6th People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 200233, P.R. China.
Exp Ther Med ; 12(6): 4017-4024, 2016 Dec.
Article em En | MEDLINE | ID: mdl-28105133
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Risk_factors_studies Idioma: En Revista: Exp Ther Med Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Risk_factors_studies Idioma: En Revista: Exp Ther Med Ano de publicação: 2016 Tipo de documento: Article